Current Report ESPI 23/2025

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow, Poland (“Company”, “Ryvu”) hereby announces that the following shareholders controlled at least 5% of the vote at the General Shareholders Meeting of the Company (“General Meeting”) convened on June 26^th, 2025:

1. Paweł Przewięźlikowski: 3,982,160 shares of the Company, which entitled to exercise 7,482,160 votes, which constituted respectively 34.45 % of shares at the GM and 49.69% of votes at the GM and 27.54% in the total number of votes.
2. Nationale-Nederlanden Otwarty Fundusz Emerytalny: 1,385,000 shares in the Company, which entitled to exercise 1,385,000 votes, which constituted 11.98% of shares at the GM and 9.20% of votes at the GM and 5.11% of the total number of votes.
3. Allianz Polska Otwarty Fundusz Emerytalny: 2,132,540 shares of the Company, which entitled to exercise 2,132,540 votes, which constituted respectively 18.45% of shares at the GM and 14.16% of votes at the GM and 7.85% in the total number of votes.
4. BioNTech SE: 1.917.437 shares of the Company, which entitled to exercise 1,917,437 votes, which constituted respectively 16.59% of shares at the GM and 12.73% of votes at the GM and 7.06% in the total number of votes.

 

According to the attendance list, shareholders holding 11,557,727 shares entitling them to exercise 15,057,727 votes were represented at the GM.

The total number of shares in the Company is 23,120,148, entitling to 27,170,148 votes.

Disclaimer: This English language translation has been prepared solely for the convenience of English speaking readers. Despite all the efforts devoted to this translation, certain discrepancies, omissions or approximations may exist. In case of any differences between the Polish and the English versions, the Polish version shall prevail. Ryvu Therapeutics S.A., its representatives and employees decline all responsibility in this regard.

 

Legal basis: Article 56.1.2 of the Act on Offerings

Representatives of the Issuer:

• Paweł Przewięźlikowski – President of the Management Board
• Kamil Sitarz – Member of the Management Board